Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Cancer cell - 39(2021), 11 vom: 08. Nov., Seite 1445-1447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McKenzie, Duncan R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 19.11.2021 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccell.2021.10.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332182967 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332182967 | ||
| 003 | DE-627 | ||
| 005 | 20240320232637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccell.2021.10.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM332182967 | ||
| 035 | |a (NLM)34678151 | ||
| 035 | |a (PII)S1535-6108(21)00545-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McKenzie, Duncan R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.11.2021 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Muñoz-Ruiz, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Monin, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Alaguthurai, Thanussuyah |e verfasserin |4 aut | |
| 700 | 1 | |a Lechmere, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Abdul-Jawad, Sultan |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Rosalind |e verfasserin |4 aut | |
| 700 | 1 | |a Sychowska, Kamila |e verfasserin |4 aut | |
| 700 | 1 | |a Seow, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Tremain, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Gousis, Charalampos |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo-Vila, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Vidler, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Owczarczyk, Kasia |e verfasserin |4 aut | |
| 700 | 1 | |a Swampillai, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Kristeleit, Hartmut |e verfasserin |4 aut | |
| 700 | 1 | |a Malim, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Fields, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Patten, Piers E M |e verfasserin |4 aut | |
| 700 | 1 | |a Papa, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a North, Bernard V |e verfasserin |4 aut | |
| 700 | 1 | |a Tree, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Doores, Katie J |e verfasserin |4 aut | |
| 700 | 1 | |a Hayday, Adrian C |e verfasserin |4 aut | |
| 700 | 1 | |a Irshad, Sheeba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer cell |d 2002 |g 39(2021), 11 vom: 08. Nov., Seite 1445-1447 |w (DE-627)NLM119589826 |x 1878-3686 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:11 |g day:08 |g month:11 |g pages:1445-1447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccell.2021.10.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 11 |b 08 |c 11 |h 1445-1447 | ||